|
Oramed Begins Studies on its Oral Insulin Capsule at Hadassah Medical Center
JERUSALEM, Israel | April 14, 2008 | Oramed Pharmaceuticals, Inc., (OTCBB: ORMP, www.oramed.com), a developer of oral delivery systems, commenced Phase 2A studies on its oral insulin capsule at the Hadassah Medical Center in Jerusalem, Israel yesterday. The Phase 2A trial is focused on assessing the safety and efficacy of the oral insulin capsule on 10 type 2 diabetes patients. This study is a continuation of the recently successfully completed Phase 1 studies in Israel.
“We are pleased to have achieved this milestone of beginning Phase 2A clinical trials in Israel in the second quarter of this year,” said Nadav Kidron, CEO of Oramed Pharmaceuticals. “We have had much success with our past clinical trials, and are on schedule with reaching our planned milestones and hope that Oramed’s oral insulin capsule will succeed in revolutionizing the current treatment for diabetes.”
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is an Israeli-based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimens. Oramed is currently developing an orally ingestible insulin capsule for the treatment of diabetes. The company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information please visit our website at: www.oramed.com.
SOURCE: Oramed Pharmaceuticals, Inc. |
